Literature DB >> 9719480

Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance.

C Lanzi1, P Perego, R Supino, S Romanelli, T Pensa, N Carenini, I Viano, D Colangelo, R Leone, P Apostoli, G Cassinelli, R A Gambetta, F Zunino.   

Abstract

In an attempt to examine the cellular changes associated with cisplatin resistance, we selected a cisplatin-resistant (A43 1/Pt) human cervix squamous cell carcinoma cell line following continuous in vitro drug exposure. The resistant subline was characterized by a 2.5-fold degree of resistance. In particular, we investigated the expression of cellular defence systems and other cellular factors probably involved in dealing with cisplatin-induced DNA damage. Resistant cells exhibited decreased platinum accumulation and reduced levels of DNA-bound platinum and interstrand cross-link frequency after short-term drug exposure. Analysis of the effect of cisplatin on cell cycle progression revealed a cisplatin-induced G2M arrest in sensitive and resistant cells. Interestingly, a slowdown in S-phase transit was found in A431/Pt cells. A comparison of the ability of sensitive and resistant cells to repair drug-induced DNA damage suggested that resistant cells were able to tolerate higher levels of cisplatin-induced DNA damage than their parental counterparts. Analysis of the expression of proteins involved in DNA mismatch repair showed a decreased level of MSH2 in resistant cells. Since MSH2 seems to be involved in recognition of drug-induced DNA damage, this change may account for the increased tolerance to DNA damage observed in the resistant subline. In conclusion, the involvement of accumulation defects and the increased tolerance to cisplatin-induced DNA damage in these cisplatin-resistant cells support the notion that multiple changes contribute to confer a low level of cisplatin resistance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9719480     DOI: 10.1016/s0006-2952(97)00599-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Apoptosis-related mRNA expression profiles of ovarian cancer cell lines following cisplatin treatment.

Authors:  Joohee Yoon; Eung-Sam Kim; Sung Jong Lee; Chang-Wook Park; Hyung Jin Cha; Bee Hak Hong; Kwan Yong Choi
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

2.  Synthesis, characterization, and biological activity of platinum II, III, and IV pivaloamidine complexes.

Authors:  Marilù Sinisi; Valentina Gandin; Teresa Saltarella; Francesco P Intini; Concetta Pacifico; Christine Marzano; Giovanni Natile
Journal:  J Biol Inorg Chem       Date:  2014-05-22       Impact factor: 3.358

Review 3.  Role of copper transporters in platinum resistance.

Authors:  Deepak Kilari; Elizabeth Guancial; Eric S Kim
Journal:  World J Clin Oncol       Date:  2016-02-10

4.  Solution behaviour and biological activity of bisamidine complexes of platinum(II).

Authors:  C Marzano; S Mazzega Sbovata; F Bettio; R A Michelin; R Seraglia; T Kiss; A Venzo; R Bertani
Journal:  J Biol Inorg Chem       Date:  2007-01-09       Impact factor: 3.862

Review 5.  Molecular mechanisms of cisplatin resistance in cervical cancer.

Authors:  Haiyan Zhu; Hui Luo; Wenwen Zhang; Zhaojun Shen; Xiaoli Hu; Xueqiong Zhu
Journal:  Drug Des Devel Ther       Date:  2016-06-07       Impact factor: 4.162

6.  Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas.

Authors:  Katherine V Clark-Knowles; Mary K Senterman; Olga Collins; Barbara C Vanderhyden
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

7.  Integral membrane protein 2A enhances sensitivity to chemotherapy via notch signaling pathway in cervical cancer.

Authors:  Yan Li; Jianhua Wang; Chengzhen Gao; Qiyan Hu; Xiaogang Mao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.